Extra proxy material
Open the filing on sec.gov
Aytu BioPharma, Inc. (AYTU)
Nasdaq: AYTU · Pharmaceutical Preparations · Denver, CO · filing with the SEC since 2007
The companyfiscal 2026, as filed
Revenue$57.6M-13.3%
Net income-$14.3M-5.1%
Earnings per share$-1.16+46.3%
Operating cash flow$3.3M+269.4%
Cash$26.3M-15.0%
Debt$9.1M-16.5%
Shareholders’ equity$35.3M+86.0%
Shares, diluted12.3M+96.2%
Return on equity-40.4%
The recordfrom its filings
Filings in 202622
Newest filingOct 27 · DEFA14A
Annual reportSep 22, 2026
Quarterly reportMay 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted27
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $57.6MNet income -$14.3MCash from operations $3.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Proxy statement
Open the filing on sec.gov
Annual report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.